NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has partnered with NHL Hall-of-Famer Henrik Lundqvist to launch the Life DisRPted campaign, focusing on raising awareness of recurrent pericarditis. This national initiative aims to promote early diagnosis and treatment of this painful, debilitating chronic autoinflammatory disease.
Lundqvist, diagnosed with recurrent pericarditis in 2021, shares his personal journey in a video titled 'Comeback After Comeback'. The campaign website, LifeDisRPted.com, features this video along with a downloadable Doctor Discussion Guide to help patients communicate with healthcare providers.
Dr. Antonio Abbate, Professor of Cardiology at The University of Virginia, emphasizes the importance of early diagnosis and proactive collaboration with healthcare providers in managing recurrent pericarditis. The campaign seeks to support patients, reduce feelings of isolation, and encourage self-advocacy in disease management.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) ha collaborato con il membro della Hall of Fame NHL Henrik Lundqvist per lanciare la campagna Life DisRPted, che si concentra sull'aumento della consapevolezza riguardo la pericardite ricorrente. Questa iniziativa nazionale mira a promuovere la diagnosi precoce e il trattamento di questa dolorosa e debilitante malattia cronica autoinfiammatoria.
Lundqvist, diagnosticato con pericardite ricorrente nel 2021, condivide il suo percorso personale in un video intitolato 'Comeback After Comeback'. Il sito web della campagna, LifeDisRPted.com, presenta questo video insieme a una Guida alla Discussione con il Medico scaricabile, per aiutare i pazienti a comunicare con i professionisti della salute.
Il Dott. Antonio Abbate, Professore di Cardiologia presso l'Università della Virginia, sottolinea l'importanza di una diagnosi tempestiva e di una collaborazione proattiva con i fornitori di assistenza sanitaria nella gestione della pericardite ricorrente. La campagna mira a supportare i pazienti, ridurre i sentimenti di isolamento e incoraggiare l'autodifesa nella gestione della malattia.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) se ha asociado con el miembro del Salón de la Fama de la NHL Henrik Lundqvist para lanzar la campaña Life DisRPted, que se centra en aumentar la conciencia sobre la pericarditis recurrente. Esta iniciativa nacional tiene como objetivo promover el diagnóstico y tratamiento temprano de esta dolorosa y debilitante enfermedad crónica autoinflamatoria.
Lundqvist, diagnosticado con pericarditis recurrente en 2021, comparte su trayectoria personal en un video titulado 'Comeback After Comeback'. El sitio web de la campaña, LifeDisRPted.com, presenta este video junto con una Guía de Discusión con el Médico para ayudar a los pacientes a comunicarse con los proveedores de atención médica.
El Dr. Antonio Abbate, Profesor de Cardiología en la Universidad de Virginia, enfatiza la importancia del diagnóstico temprano y la colaboración proactiva con los proveedores de salud en la gestión de la pericarditis recurrente. La campaña busca apoyar a los pacientes, reducir los sentimientos de aislamiento y fomentar la autodefensa en la gestión de la enfermedad.
Kiniksa Pharmaceuticals (Nasdaq: KNSA)는 NHL 명예의 전당 선수 Henrik Lundqvist와 함께 Life DisRPted 캠페인을 시작하여 재발성 심막염에 대한 인식을 높이고 있습니다. 이 국가적 이니셔티브는 이 고통스럽고 쇠약하게 하는 만성 자가 염증 질환에 대한 조기 진단과 치료를 촉진하는 것을 목표로 합니다.
2021년에 재발성 심막염 진단을 받은 Lundqvist는 'Comeback After Comeback'라는 제목의 비디오에서 자신의 개인적인 여정을 공유합니다. 캠페인 웹사이트인 LifeDisRPted.com에는 이 비디오와 함께 환자가 의료 제공자와 의사소통할 수 있도록 돕는 다운로드 가능한 의사와의 토론 가이드가 포함되어 있습니다.
버지니아 대학교의 심장학 교수인 Antonio Abbate 박사는 재발성 심막염 관리에서 조기 진단 및 의료 제공자와의 적극적인 협력의 중요성을 강조합니다. 이 캠페인은 환자를 지원하고 고립감을 줄이며 질병 관리에서 자기 옹호를 장려하는 것을 목표로 합니다.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) s'est associé au membre de la Huitième Hall of Fame de la NHL Henrik Lundqvist pour lancer la campagne Life DisRPted, qui vise à sensibiliser à la péricardite récidivante. Cette initiative nationale a pour but de promouvoir un diagnostic et un traitement précoces de cette maladie auto-inflammatoire chronique douloureuse et débilitante.
Lundqvist, diagnostiqué avec une péricardite récidivante en 2021, partage son parcours personnel dans une vidéo intitulée 'Comeback After Comeback'. Le site Web de la campagne, LifeDisRPted.com, présente cette vidéo ainsi qu'un Guide de Discussion avec le Médecin téléchargeable pour aider les patients à communiquer avec les prestataires de soins de santé.
Le Dr Antonio Abbate, professeur de cardiologie à l'Université de Virginie, souligne l'importance d'un diagnostic précoce et d'une collaboration proactive avec les prestataires de soins de santé dans la gestion de la péricardite récidivante. La campagne vise à soutenir les patients, à réduire le sentiment d'isolement et à encourager l'autodéfense dans la gestion de la maladie.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) hat sich mit NHL Hall-of-Famer Henrik Lundqvist zusammengetan, um die Kampagne Life DisRPted zu starten, die darauf abzielt, das Bewusstsein für wiederkehrende Perikarditis zu schärfen. Diese nationale Initiative zielt darauf ab, eine frühzeitige Diagnose und Behandlung dieser schmerzhaften, schwächenden chronischen Autoentzündungserkrankung zu fördern.
Lundqvist, bei dem 2021 wiederkehrende Perikarditis diagnostiziert wurde, teilt seinen persönlichen Werdegang in einem Video mit dem Titel 'Comeback After Comeback'. Die Kampagnenwebsite LifeDisRPted.com zeigt dieses Video zusammen mit einem herunterladbaren Arzt-Diskussionsleitfaden, um den Patienten zu helfen, mit den Gesundheitsdienstleistern zu kommunizieren.
Dr. Antonio Abbate, Professor für Kardiologie an der Universität von Virginia, betont die Bedeutung einer frühen Diagnose und einer proaktiven Zusammenarbeit mit den Gesundheitsdienstleistern bei der Behandlung von wiederkehrender Perikarditis. Die Kampagne zielt darauf ab, Patienten zu unterstützen, das Gefühl der Isolation zu verringern und die Selbstvertretung im Umgang mit der Krankheit zu fördern.
- None.
- None.
– Life DisRPted is an educational campaign aimed at promoting early diagnosis and treatment of recurrent pericarditis, a painful and debilitating chronic autoinflammatory disease –
LONDON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company, has teamed up with National Hockey League™ (NHL) Hall-of-Famer, Henrik Lundqvist, to launch Life DisRPted, a national campaign focused on raising awareness of recurrent pericarditis, its impact on quality of life, and the critical importance of early diagnosis and treatment. Lundqvist was diagnosed with recurrent pericarditis in 2021, ultimately leading to his decision to retire from the NHL.
“When I was first diagnosed with recurrent pericarditis, it felt like being hit by a train. The persistent pain of pericarditis flares ultimately kept me from returning to the NHL and the game I love. In addition to the physical toll, I felt I was missing out on life with my family and friends,” said Henrik Lundqvist, Hall of Fame former goaltender for the New York Rangers. “While this experience has deeply affected me, my family, and my career, it is possible to take back control with a proactive approach. I want to use the Life DisRPted campaign to raise awareness of recurrent pericarditis and encourage others to advocate for early diagnosis and treatment.”
“There is a large unmet need for patients with recurrent pericarditis. Many patients experience delayed diagnosis, which can leave them feeling isolated or helpless,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “The goal of this campaign is to let patients with recurrent pericarditis know that they are not alone and do not have to suffer in silence. With the right medical support, recurrent pericarditis patients can manage this chronic disruption in their lives.”
As part of Life DisRPted, Lundqvist’s journey is featured in a video titled “Comeback After Comeback,” alongside insights from Dr. Antonio Abbate, M.D., Ph.D., Professor of Cardiology at The University of Virginia. The video highlights Lundqvist’s personal experience with recurrent pericarditis, from his diagnosis to how it disrupted his life and career, while stressing the importance of self-advocacy in managing the disease. The video is available on the campaign website, LifeDisRPted.com, which also features a downloadable Doctor Discussion Guide to help patients prepare for conversations with their healthcare providers.
“Recurrent pericarditis is a rare disease, and its symptoms often mimic those of other conditions like heart attacks, gastritis, or musculoskeletal pain, making it difficult to diagnose,” said Dr. Abbate. “Recurrent pericarditis flares can be cyclical, with each flare increasing the risk of another, which makes early diagnosis and proactive collaboration with a healthcare provider essential. If you’ve been diagnosed with or think you have recurrent pericarditis, it’s important to talk with your doctor. By understanding the disease, you can work together on a plan to treat recurrent pericarditis.”
To learn about recurrent pericarditis and hear more about Henrik Lundqvist's personal experience, visit LifeDisRPted.com.
A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d0e3b25b-09eb-4f6e-b93a-893e0a29c4d0
About Recurrent Pericarditis
Recurrent pericarditis is a painful and debilitating chronic autoinflammatory cardiovascular disease marked by inflammation of the pericardium and is often associated with changes in electrical conduction and sometimes buildup of fluid around the heart, called pericardial effusion. Recurrent pericarditis symptoms have an impact on quality of life, limit physical activities, and lead to frequent emergency department visits and hospitalizations. Data show that approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year. Of that group, approximately 14,000 patients experience two or more recurrences due to persistent underlying disease or inadequate response to conventional therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids.
About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.
Every Second Counts! ®
Kiniksa Investor Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com
Kiniksa Media Contact
Tyler Gagnon
(781) 431-9100
tgagnon@kiniksa.com
FAQ
What is the Life DisRPted campaign launched by Kiniksa Pharmaceuticals (KNSA)?
How did recurrent pericarditis affect Henrik Lundqvist's NHL career?
What resources does the Life DisRPted campaign offer for recurrent pericarditis patients?
Why is early diagnosis important for recurrent pericarditis, according to the Life DisRPted campaign?
